Timothy D. Shafman
/content/dam/us-photography/doctor-headshots/dr-timothy-shafman-2.jpg

Timothy D. Shafman

Timothy D. Shafman
Timothy D.
Shafman
MD
Radiation Oncologist

Languages spoken

English

Expert in

Lung cancer, Brain tumors, Breast cancer

Overview

Centers

Venice (Radiation oncology)
Venice (Radiation oncology)

901 S. Tamiami Trail
Venice, Florida 34285

27.0851132, -82.4380293
/en/our-locations/venice-icp

Timothy D. Shafman, MD, graduated with honors from Harvard Medical School and spent the first ten years of his career conducting research on cancer-related issues and caring for patients with brain tumors and lung cancer. Dr. Shafman joined GenesisCare in June 2004 and has worked in Port Charlotte, FL, Rhode Island and Massachusetts. He previously served as Medical Director of Rhode Island and Massachusetts and as U.S. CMO of Radiation Oncology, Quality and Safety. He currently serves as the Medical Director of Venice and Sarasota and is excited to be back in Southwest FL. 

Dr. Shafman has published over 50 peer-reviewed articles on a range of topics including lung cancer, brain tumors, breast cancer and the genetics of radiation sensitivity. 

 

Career positions

  • US CMO, Radiation Oncology and Quality & Safety, GenesisCare US
  • Assistant Professor, Harvard Medical School, Department of Radiation Oncology
  • Assistant Professor, Duke University Medical School, Department of Radiation Oncology
  • SVP, National Medical Director, 21st Century Oncology

Education

Universities

  • Brandeis University, Bachelor of Arts, Waltham, MA
  • Harvard Medical School Massachusetts Institute of Technology, Health Science & Technology, Medical Degree, Cum Laude, Boston, MA

Residencies

  • Harvard Medical School Joint Center for Radiation Therapy, Radiation Oncology, Chief Resident, Boston, MA

Internships

  • Brigham & Women’s Hospital, Internal Medicine, Boston, MA

Professional associations

Accomplishments

Publications

  • Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
  • Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma.
  • Patient-reported quality of life after stereotactic body radiation therapy vs. moderate hypofractionation for clinically localized prostate
  • Patient-reported quality of life after stereotactic body radiation therapy vs. moderate hypofractionation for clinically localized prostate
  • A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy
  • Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model. View publication

Presentations

Z091420165

Johnson SB, Soulos PR, Shafman TD, Mantz CA, Ross R, Finkelstein SE, Collins SP, Suy S, Brower JV, Ritter MA, King CR, Kupelian PA, Horwitz EM, Pollack A, Abramowitz MC, Hallman MA, Faria S, Gross CP, Yu JB, 2016, ASTRO

Z091420164

Stahl JM, Ross R, Harder EM, Mancini BR, Soulos PR, Finkelstein S, Shafman TD, Husain ZA, Evans SB, Yu JB, Gross CP, Decker RH, 2016, ASTRO

Z091420163

Hong J, Gross CP, Shafman T, Hu X, Yu J, Ross R, Finkelstein S, Park H, Soulos P, Evans S., 2016, ASTRO

Z091420162

Finkelstein SE, Forman J, Fernandez E, Chen C, Lieberfarb M, Salenius SA, Shafman T, and Mantz CA, 2016, ASTRO

Z080120161

Alfred Tinger MD, Elizabeth Chabner MD, Sharon Salenius MPH, Evelyn Staviski RTT, Neil Beitch RTT, CMD, Ulrich Hermanto, MD, John Del Rowe MD, Timothy Shafman MD, 2016, RSNA

Thank you for submitting.

We will be in touch within 24 hours.

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

Our staff will provide answers to your questions within 24 hours. Otherwise, if you have a medical emergency please call 911.

*Indicates a required field